

Supporting Information

**Zinc-Catalyzed Oxidative Reaction of Ynamides with Phenols and Thiophenols:
Highly Site-Selective Synthesis of Versatile α -Aryloxy Amides and α -Arylthio
Amides**

Peng-Peng Ruan,[#] Cang-Hai Shen,[#] Long Li, Chao-Yue Liu and Long-Wu Ye*


State Key Laboratory of Physical Chemistry of Solid Surfaces & The Key Laboratory
for Chemical Biology of Fujian Province, Department of Chemistry, Xiamen
University, Xiamen 361005, China

Content	Page number
General	2
Optimization of Reaction Conditions	2
Preparation of Starting Materials	3
General Procedure for the Preparation of α-Functionalized Amides	8
¹H and ¹³C NMR Spectra	26

General Information. Ethyl acetate (ACS grade), hexanes (ACS grade) and anhydrous 1, 2-dichloroethane (ACS grade) were obtained commercially and used without further purification. Methylene chloride, tetrahydrofuran and diethyl ether were purified according to standard methods unless otherwise noted. Commercially available reagents were used without further purification. Reactions were monitored by thin layer chromatography (TLC) using pre-coated silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). Infrared spectra were recorded on a Nicolet AVATER FTIR330 spectrometer as thin film and are reported in reciprocal centimeter (cm^{-1}). Mass spectra were recorded with Micromass QTOF2 Quadrupole/Time-of-Flight Tandem mass spectrometer using electron spray ionization.

^1H NMR spectra and ^{13}C NMR spectra were recorded on a Bruker AV-400 spectrometer and a Bruker AV-500 spectrometer in chloroform- d_3 . For ^1H NMR spectra, chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. For ^{13}C NMR spectra, chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard.


Table S1. Effects of catalyst and oxidant on the reaction of thiophenol with **1a**^a




entry	catalyst	oxidant (R)	yield (%) ^b		
			4a	2aa	2ab
1	Zn(OTf) ₂	3a (2,6-Br ₂)	30	<1	<5
2	Zn(OTf) ₂	3b (2,6-Me ₂)	78	<1	<5
3	Zn(OTf) ₂	3c (3,5-Cl ₂)	69	<5	<5
4	Sc(OTf) ₃	3b (2,6-Me ₂)	67	<5	<5
5	Y(OTf) ₃	3b (2,6-Me ₂)	70	<1	8
6	In(OTf) ₃	3b (2,6-Me ₂)	72	<1	<5

^a Reaction conditions: [**1a**] = 0.10 M. ^b Estimated by ^1H NMR using diethyl phthalate as internal reference.


The data of the following ynamides **1** (**1a**, **1b**, **1l**, **1m**) were reported in our previous work.^{1,2}



Representative synthetic procedures for the preparation of ynamides **1**:³




4-bromo-*N*-methyl-*N*-(phenylethynyl)benzenesulfonamide (1c)



1c

White solid (mp 79 – 81 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.85 – 7.78 (m, 2H), 7.76 – 7.69 (m, 2H), 7.38 – 7.33 (m, 2H), 7.32 – 7.27 (m, 3H), 3.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 134.8, 132.4, 131.3, 129.0, 128.9, 128.2, 128.0, 122.1, 83.2, 69.2, 39.2; IR (neat): 2923, 2234, 2099, 1368, 1168, 756; MS (ESI, m/z) 372 (M + Na⁺); HRESIMS Calcd for [C₁₅H₁₂BrNNaO₂S]⁺ (M + Na⁺) 371.9664, found 371.9661.


4-bromo-*N*-phenyl-*N*-(phenylethynyl)benzenesulfonamide (1d)



1d

White solid (mp 100 – 101 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.65 – 7.63 (m, 2H), 7.59 – 7.57 (m, 2H), 7.40 – 7.28 (m, 10H); ¹³C NMR (100 MHz, CDCl₃) δ 138.5, 134.7, 132.2, 131.5, 129.6, 129.3, 129.2, 128.5, 128.3, 128.2, 126.2, 122.2, 82.3, 70.7; IR (neat): 3063, 2925, 2239, 1573, 1378, 1175, 741, 605; MS (ESI, m/z) 434 (M + Na⁺); HRESIMS Calcd for [C₂₀H₁₄BrNNaO₂S]⁺ (M + Na⁺) 433.9821, found 433.9823.


***N*-allyl-4-bromo-*N*-(phenylethynyl)benzenesulfonamide (1e)**



1e

White solid (mp 85 – 86 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.80 (m, 2H), 7.71 – 7.69 (m, 2H), 7.36 – 7.33 (m, 2H), 7.29 – 7.25 (m, 3H), 5.84 – 5.74 (m, 1H), 5.33 – 5.24 (m, 2H), 4.07 (d, 2H, *J* = 6.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 140.1, 136.1, 135.0, 132.5, 129.1, 129.0, 128.6, 128.4, 126.0, 106.9, 85.2, 68.9, 39.3; IR (neat): 3085, 2923, 2237, 1574, 1371, 1173, 740, 621; MS (ESI, m/z) 398 (M + Na⁺); HRESIMS Calcd for [C₁₇H₁₄BrNNaO₂S]⁺ (M + Na⁺) 397.9821, found 397.9822.


4-bromo-*N*-((4-fluorophenyl)ethynyl)-*N*-methylbenzenesulfonamide (1f)



1f

White solid (mp 105 – 106 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.82 – 7.80 (m, 2H), 7.74 – 7.72 (m, 2H), 7.36 – 7.32 (m, 2H), 7.02 – 6.97 (m, 2H), 3.16 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.4 (d, *J* = 249.6 Hz), 135.1, 133.6 (d, *J* = 8.4 Hz), 132.5, 129.2, 129.1, 118.3 (d, *J* = 3.4 Hz), 115.6 (d, *J* = 22.1 Hz), 82.8, 68.2, 39.3; IR (neat): 1933, 2240, 1509, 1371, 1169, 752, 566; MS (ESI, m/z) 390 (M + Na⁺); HRESIMS Calcd for [C₁₅H₁₁BrFNNaO₂S]⁺ (M + Na⁺) 389.9570, found 389.9572.


4-bromo-*N*-((3-fluorophenyl)ethynyl)-*N*-methylbenzenesulfonamide (1g)



1g

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.82 – 7.80 (m, 2H), 7.74 – 7.72 (m, 2H), 7.28 – 7.23 (m, 1H), 7.14 – 7.12 (m, 1H), 7.05 – 6.97 (m, 2H), 3.17 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.3 (d, $J = 246.6$ Hz), 135.1, 132.6, 129.9 (d, $J = 8.8$ Hz), 129.2, 129.1, 127.1 (d, $J = 3.1$ Hz), 124.2 (d, $J = 9.7$ Hz), 118.0 (d, $J = 22.9$ Hz), 115.3 (d, $J = 21.2$ Hz), 84.1, 68.4, 39.3; IR (neat): 2925, 2239, 1575, 1371, 1175, 750, 593; MS (ESI, m/z) 390 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{15}\text{H}_{11}\text{BrFNNaO}_2\text{S}]^+$ ($\text{M} + \text{Na}^+$) 389.9570, found 389.9572.


4-bromo-*N*-((4-chlorophenyl)ethynyl)-*N*-methylbenzenesulfonamide (1h)



1h

White solid (mp 120 – 121 °C). ^1H NMR (400 MHz, CDCl_3) δ 7.81 – 7.79 (m, 2H), 7.74 – 7.72 (m, 2H), 7.30 – 7.25 (m, 4H), 3.17 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 135.0, 134.0, 132.6, 132.5, 129.1, 128.6, 120.8, 84.1, 68.4, 39.3; IR (neat): 2930, 2236, 1574, 1372, 1170, 1010, 742, 596; MS (ESI, m/z) 406 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{15}\text{H}_{11}\text{BrClNNaO}_2\text{S}]^+$ ($\text{M} + \text{Na}^+$) 405.9275, found 405.9279.


4-bromo-*N*-((4-bromophenyl)ethynyl)-*N*-methylbenzenesulfonamide (1i)



1i

White solid (mp 133 – 134 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.81 – 7.79 (m, 2H), 7.74 – 7.72 (m, 2H), 7.42 (d, 2H, *J* = 8.4 Hz), 7.21 (d, 2H, *J* = 8.8 Hz), 3.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 135.1, 132.8, 132.6, 131.5, 129.1, 122.2, 121.3, 84.3, 68.5, 39.3; IR (neat): 2930, 2236, 1574, 1372, 1069, 742, 596; MS (ESI, *m/z*) 450 (M + Na⁺); HRESIMS Calcd for [C₁₅H₁₁Br₂NNaO₂S]⁺ (M + Na⁺) 449.8769, found 449.8768.


4-bromo-*N*-methyl-*N*-(*p*-tolylethynyl)benzenesulfonamide (**1j**)



1j

White solid (mp 83 – 84 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.82 – 7.80 (m, 2H), 7.73 – 7.70 (m, 2H), 7.25 (d, 2H, *J* = 8.0 Hz), 7.10 (d, 2H, *J* = 8.0 Hz), 3.16 (s, 3H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 138.3, 135.1, 132.5, 131.6, 129.2, 129.1, 129.0, 119.1, 82.5, 69.3, 39.4, 21.4; IR (neat): 2923, 2237, 1574, 1370, 1182, 750, 565; MS (ESI, *m/z*) 386 (M + Na⁺); HRESIMS Calcd for [C₁₆H₁₄BrNNaO₂S]⁺ (M + Na⁺) 385.9821, found 385.9819.


(*E*)-4-bromo-*N*-methyl-*N*-(4-phenylbut-3-en-1-yn-1-yl)benzenesulfonamide (**1k**)



1k

White solid (mp 109 – 111 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, 2H, *J* = 8.4 Hz), 7.71 (d, 2H, *J* = 8.4 Hz), 7.36 – 7.26 (m, 5H), 6.84 (d, 1H, *J* = 8.4 Hz), 6.20 (d, 1H, *J* = 8.4 Hz), 3.12 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 140.1, 136.1, 135.0, 132.5, 129.1, 129.0, 128.6, 128.4, 126.0, 106.9, 85.2, 68.9, 39.3; IR (neat): 3028, 2224, 1573, 1370, 745, 562; MS (ESI, *m/z*) 398 (M + Na⁺); HRESIMS Calcd for [C₁₇H₁₄BrNNaO₂S]⁺ (M + Na⁺) 397.9821, found 397.9821.


***N*-((4-bromophenyl)ethynyl)-*N*,4-dimethylbenzenesulfonamide (1n)**



1n


White solid (mp 116 – 118 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, 2H, *J* = 8.4 Hz), 7.44 – 7.34 (m, 4H), 7.24 – 7.17 (m, 2H), 3.14 (s, 3H), 2.46 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.9, 133.1, 132.6, 131.4, 129.8, 127.7, 121.8, 121.6, 85.0, 68.1, 39.1, 21.6; IR (neat): 2928, 2234, 2101, 1365, 1265, 1168, 739; MS (ESI, *m/z*) 386 (*M* + Na⁺); HRESIMS Calcd for [C₁₆H₁₄BrNNaO₂S]⁺ (*M* + Na⁺) 385.9821, found 385.9823.

***N*-((4-methoxyphenyl)ethynyl)-*N*,4-dimethylbenzenesulfonamide (1o)**



1o


White solid (mp 66 – 68 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, 2H, *J* = 8.0 Hz), 7.36 (d, 2H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.4 Hz), 6.81 (d, 2H, *J* = 8.4 Hz), 3.79 (s, 3H), 3.12 (s, 3H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.4, 144.6, 133.2, 132.9, 129.6, 127.6, 114.3, 113.8, 82.4, 68.5, 55.1, 39.2, 21.4; IR (neat): 2934, 2233, 1604, 1511, 1456, 1364, 1248, 1165, 727, 567; MS (ESI, *m/z*) 338 (*M* + Na⁺); HRESIMS Calcd for [C₁₇H₁₇NNaO₃S]⁺ (*M* + Na⁺) 338.0821, found 338.0824.



General procedure for the synthesis of 2:


2,6-dibromopyridine *N*-oxide (151.7 mg, 0.6 mmol), ArOH (0.6 mmol) and Zn(OTf)₂ (21.8 mg, 0.06 mmol) were added in this order to the ynamide **1** (0.30 mmol) in DCM (3.0 mL) at room temperature. The reaction mixture was stirred at 40 °C and the progress of the reaction was monitored by TLC. The reaction typically took 4 h. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired product **2**.

N-methyl-2-phenoxy-2-phenyl-*N*-tosylacetamide (**2a**)



Compound **2a** was prepared in 61% yield according to the general procedure (Table 2, entry 1). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.46 (m, 4H), 7.39 – 7.37 (m, 3H), 7.25 – 7.17 (m, 4H), 7.00 – 6.96 (m, 1H), 6.90 – 6.88 (m, 2H), 6.49 (s, 1H), 3.19 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 157.2, 145.0, 135.0, 134.4, 129.7, 129.6, 129.1, 128.9, 127.9, 127.8, 122.0, 115.6, 79.5, 33.0, 21.6; IR (neat): 2921, 1709 (s), 1597, 1494, 1358, 1170, 751, 547; MS (ESI, m/z) 418 (M + Na⁺); HRESIMS Calcd for [C₂₂H₂₁NNaO₄S]⁺ (M + Na⁺) 418.1083, found 418.1084.


N-methyl-2-oxo-2-phenyl-*N*-tosylacetamide (**2aa**)



2aa

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, 2H, $J = 7.2$ Hz), 7.88 (d, 2H, $J = 8.0$ Hz), 7.66 – 7.62 (m, 1H), 7.55 – 7.51 (m, 2H), 7.39 (d, 2H, $J = 8.0$ Hz), 3.24 (s, 3H), 2.46 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 188.0, 167.2, 145.9, 134.4, 133.4, 132.7, 130.1, 129.6, 128.8, 128.3, 30.7, 21.7; IR (neat): 2922, 1681 (s), 1371, 1165, 947, 716, 663, 593; MS (ESI, m/z) 340 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{16}\text{H}_{15}\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 340.0614, found 340.0613.


***N*-methyl-2-phenyl-*N*-tosylacetamide (2ab)**



2ab

Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, 2H, $J = 8.4$ Hz), 7.31 – 7.24 (m, 5H), 7.13 – 7.11 (m, 2H), 4.03 (s, 2H), 3.27 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.2, 144.9, 135.9, 133.4, 129.8, 129.3, 128.5, 127.4, 127.1, 43.0, 33.2, 21.5; IR (neat): 2923, 1697 (s), 1357, 1167, 1075, 673, 583, 549; MS (ESI, m/z) 326 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{16}\text{H}_{17}\text{NNaO}_3\text{S}]^+$ ($\text{M} + \text{Na}^+$) 326.0821, found 326.0820.

***N*-methyl-*N*-(methylsulfonyl)-2-phenoxy-2-phenylacetamide (2b)**




2b

Compound **2b** was prepared in 59% yield according to the general procedure (Table 2,

entry 2). White solid (mp 112 – 114 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.53 – 7.52 (m, 2H), 7.45 – 7.40 (m, 3H), 7.31 – 7.25 (m, 2H), 7.02 – 6.96 (m, 3H), 6.40 (s, 1H), 3.25 (s, 3H), 2.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.3, 157.0, 133.9, 129.7, 129.4, 129.1, 127.9, 122.2, 115.5, 79.5, 40.6, 32.7; IR (neat): 3038, 2931, 1708 (s), 1597, 1494, 1354, 1225, 1168, 964, 755, 517; MS (ESI, m/z) 342 (M + Na⁺); HRESIMS Calcd for [C₁₆H₁₇NNaO₄S]⁺ (M + Na⁺) 342.0770, found 342.0771.


***N*-((4-bromophenyl)sulfonyl)-*N*-methyl-2-phenoxy-2-phenylacetamide (**2c**)**



2c

Compound **2c** was prepared in 74% yield according to the general procedure (Table 2, entry 3). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.53 – 7.51 (m, 2H), 7.47 – 7.38 (m, 7H), 7.26 – 7.22 (m, 2H), 7.02 – 6.98 (m, 1H), 6.88 – 6.86 (m, 2H), 6.32 (s, 1H), 3.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.7, 157.0, 136.9, 133.9, 132.2, 129.7, 129.4, 129.2, 129.1, 129.0, 127.5, 122.2, 115.5, 79.7, 33.0; IR (neat): 3064, 2925, 1710 (s), 1494, 1360, 1225, 1171, 750, 613; MS (ESI, m/z) 482 (M + Na⁺); HRESIMS Calcd for [C₂₁H₁₈BrNNaO₄S]⁺ (M + Na⁺) 482.0032, found 482.0038.

***N*-((4-bromophenyl)sulfonyl)-2-phenoxy-*N*,2-diphenylacetamide (**2d**)**




2d

Compound **2d** was prepared in 70% yield according to the general procedure (Table 2, entry 4). White solid (mp 123 – 124 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, 2H, *J* = 8.4 Hz), 7.65 (d, 2H, *J* = 8.4 Hz), 7.49 – 7.46 (m, 1H), 7.38 – 7.19 (m, 5H), 7.18 –

7.14 (m, 2H), 7.00 – 6.91 (m, 5H), 6.66 (d, 2H, $J = 8.0$ Hz), 5.33 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.7, 156.8, 137.3, 134.0, 133.7, 132.1, 130.8, 130.6, 130.5, 129.6, 129.5, 129.4, 128.7, 128.0, 122.1, 115.7, 79.0; IR (neat): 3065, 2924, 1717 (s), 1490, 1370, 1230, 1162, 747, 696, 601; MS (ESI, m/z) 544 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{26}\text{H}_{20}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 544.0189, found 544.0188.


***N*-allyl-*N*-((4-bromophenyl)sulfonyl)-2-phenoxy-2-phenylacetamide (2e)**



2e

Compound **2e** was prepared in 74% yield according to the general procedure (Table 2, entry 5). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.57 – 7.50 (m, 4H), 7.39 – 7.34 (m, 5H), 7.24 – 7.19 (m, 2H), 6.99 – 6.95 (m, 1H), 6.82 (d, 2H, $J = 8.0$ Hz), 6.18 (s, 1H), 5.74 – 5.64 (m, 1H), 5.21 – 5.17 (m, 2H), 4.46 – 4.30 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 157.0, 137.4, 133.8, 132.1, 131.9, 129.7, 129.5, 129.3, 129.1, 129.0, 127.7, 122.1, 119.0, 115.5, 79.4, 48.4; IR (neat): 3090, 1712 (s), 1574, 1494, 1362, 1226, 1171, 751, 610; MS (ESI, m/z) 508 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{23}\text{H}_{20}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 508.0189, found 508.0187.

***N*-((4-bromophenyl)sulfonyl)-2-(4-fluorophenyl)-*N*-methyl-2-phenoxyacetamide (2f)**




2f

Compound **2f** was prepared in 85% yield according to the general procedure (Table 2, entry 6). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.56 – 7.43 (m, 6H), 7.25 –

7.22 (m, 2H), 7.10 – 7.06 (m, 2H), 7.00 (t, 1H, $J = 7.2$ Hz), 6.85 (d, 2H, $J = 8.0$ Hz), 6.35 (s, 1H), 3.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.7, 163.2 (d, $J = 249.1$ Hz), 156.8, 136.9, 132.4, 130.0 (d, $J = 3.2$ Hz), 129.7, 129.6 (d, $J = 8.4$ Hz), 129.3, 129.2, 122.4, 116.0 (d, $J = 21.8$ Hz), 115.6, 78.9, 33.1; IR (neat): 3091, 2918, 1711 (s), 1574, 1492, 1224, 1172, 1011, 752, 613; MS (ESI, m/z) 500 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{BrFNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 499.9938, found 499.9941.


***N*-((4-bromophenyl)sulfonyl)-2-(3-fluorophenyl)-*N*-methyl-2-phenoxyacetamide
(2g)**



2g

Compound **2g** was prepared in 82% yield according to the general procedure (Table 2, entry 7). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.57 – 7.49 (m, 4H), 7.40 – 7.24 (m, 5H), 7.22 – 7.01 (m, 2H), 6.86 (d, 2H, $J = 8.0$ Hz), 6.33 (s, 1H), 3.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 162.9 (d, $J = 247.8$ Hz), 156.7, 136.9, 136.5 (d, $J = 7.5$ Hz), 132.3, 130.6 (d, $J = 8.1$ Hz), 129.8, 129.3, 122.9 (d, $J = 3.0$ Hz), 122.5, 116.2 (d, $J = 21.0$ Hz), 115.5, 114.5 (d, $J = 23.0$ Hz), 79.1, 33.1; IR (neat): 2919, 1718 (s), 1574, 1011, 913, 747, 613; MS (ESI, m/z) 500 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{BrFNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 499.9938, found 499.9940.


***N*-((4-bromophenyl)sulfonyl)-2-(4-chlorophenyl)-*N*-methyl-2-phenoxyacetamide
(2h)**



2h

Compound **2h** was prepared in 77% yield according to the general procedure (Table 2, entry 8). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.57 – 7.49 (m, 4H), 7.42 – 7.35 (m, 4H), 7.25 – 7.22 (m, 2H), 7.03 – 6.99 (m, 1H), 6.85 (d, 2H, $J = 7.6$ Hz), 6.34 (s, 1H), 3.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.5, 156.7, 136.9, 135.4, 132.6, 132.4, 129.8, 129.3, 129.2, 129.1, 128.9, 122.4, 115.6, 79.0, 33.1; IR (neat): 2922, 1712 (s), 1510, 1362, 1225, 1011, 748, 614; MS (ESI, m/z) 516 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{BrClNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 515.9642, found 515.9644.


2-(4-bromophenyl)-*N*-((4-bromophenyl)sulfonyl)-*N*-methyl-2-phenoxyacetamide (2i)



2i

Compound **2i** was prepared in 75% yield according to the general procedure (Table 2, entry 9). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.56 – 7.48 (m, 6H), 7.33 (d, 2H, $J = 8.4$ Hz), 7.25 – 7.21 (m, 2H), 7.02 – 6.98 (m, 1H), 6.84 (d, 2H, $J = 7.6$ Hz), 6.32 (s, 1H), 3.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 156.7, 136.8, 133.1, 132.3, 132.1, 129.7, 129.3, 129.2, 129.1, 123.5, 122.4, 115.5, 79.0, 33.1; IR (neat): 2924, 1711 (s), 1596, 1489, 1365, 1223, 1070, 749, 614; MS (ESI, m/z) 560 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{Br}_2\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 559.9137, found 559.9138.


***N*-((4-bromophenyl)sulfonyl)-*N*-methyl-2-phenoxy-2-(*p*-tolyl)acetamide (2j)**



2j

Compound **2j** was prepared in 70% yield according to the general procedure (Table 2, entry 10). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.46 (m, 4H), 7.30 – 7.17 (m, 6H), 7.01 – 6.97 (m, 1H), 6.86 (d, 2H, $J = 8.0$ Hz), 6.26 (s, 1H), 3.24 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 157.1, 139.3, 137.0, 132.2, 130.8, 129.7, 129.6, 129.4, 129.0, 127.5, 122.1, 115.5, 79.6, 33.0, 21.2; IR (neat): 2924, 1712 (s), 1574, 1488, 1363, 1226, 750, 613; MS (ESI, m/z) 496 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{22}\text{H}_{20}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 496.0189, found 496.0189.


(E)-N-((4-bromophenyl)sulfonyl)-N-methyl-4-phenoxy-4-phenylbut-2-enamide
(2k)



2k

Compound **2k** was prepared in 68% yield according to the general procedure (Table 2, entry 11). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.60 – 7.54 (m, 4H), 7.41 – 7.31 (m, 5H), 7.29 – 7.24 (m, 2H), 7.11 – 7.02 (m, 2H), 6.99 – 6.91 (m, 3H), 5.79 (d, 1H, $J = 3.2$ Hz), 3.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.5, 157.3, 147.5, 138.0, 137.9, 132.6, 129.5, 129.0, 128.9, 128.8, 128.5, 126.8, 121.6, 121.0, 116.0, 78.9, 33.1; IR (neat): 2918, 1682 (s), 1493, 1365, 1166, 751, 1173, 614; MS (ESI, m/z) 508 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{23}\text{H}_{20}\text{BrNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 508.0189, found 508.0191.


N-((4-bromophenyl)sulfonyl)-2-(4-chlorophenoxy)-N-methyl-2-phenylacetamide
(2l)



2l

Compound **2l** was prepared in 80% yield according to the general procedure (Table 2, entry 12). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, 2H, $J = 8.8$ Hz), 7.42 – 7.39 (m, 7H), 7.20 (d, 2H, $J = 9.2$ Hz), 6.81 (d, 2H, $J = 9.2$ Hz), 6.34 (s, 1H), 3.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.4, 155.5, 136.7, 133.4, 132.3, 129.5, 129.4, 129.2, 129.1, 127.7, 127.2, 116.9, 116.6, 79.9, 33.0; IR (neat): 2919, 1711 (s), 1489, 1229, 1010, 743, 613; MS (ESI, m/z) 516 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{BrClNNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 515.9642, found 515.9643.


2-(4-bromophenoxy)-N-((4-bromophenyl)sulfonyl)-N-methyl-2-phenylacetamide (2m)



2m

Compound **2m** was prepared in 77% yield according to the general procedure (Table 2, entry 13). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, 2H, $J = 8.8$ Hz), 7.42 – 7.39 (m, 7H), 7.33 (d, 2H, $J = 9.2$ Hz), 6.76 (d, 2H, $J = 9.2$ Hz), 6.33 (s, 1H), 3.20 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 156.1, 136.7, 133.5, 132.5, 132.3, 129.5, 129.3, 129.2, 129.1, 127.8, 117.4, 114.6, 79.8, 33.1; IR (neat): 2918, 1710 (s), 1574, 1486, 1364, 1230, 821, 748, 613; MS (ESI, m/z) 560 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{Br}_2\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 559.9137, found 559.9139.


**2-(3-bromophenoxy)-N-((4-bromophenyl)sulfonyl)-N-methyl-2-phenylacetamide
(2n)**



2n

Compound **2n** was prepared in 79% yield according to the general procedure (Table 2, entry 14). Pale yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.56 – 7.53 (m, 2H), 7.47 – 7.41 (m, 7H), 7.14 – 7.04 (m, 3H), 6.81 – 6.80 (m, 1H), 6.35 (s, 1H), 3.21 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 169.2, 157.7, 136.7, 133.4, 132.4, 130.8, 129.5, 129.3, 129.2, 129.1, 127.8, 125.3, 122.9, 119.1, 114.1, 79.7, 33.1; IR (neat): 3090, 2924, 1710 (s), 1574, 1473, 1364, 743, 613; MS (ESI, m/z) 560 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{21}\text{H}_{17}\text{Br}_2\text{NNaO}_4\text{S}]^+$ ($\text{M} + \text{Na}^+$) 559.9137, found 559.9138.


**N-((4-bromophenyl)sulfonyl)-2-(4-methoxyphenoxy)-N-methyl-2-phenylacetamide
(2o)**



2o

Compound **2o** was prepared in 81% yield according to the general procedure (Table 2, entry 15). Pale yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.54 – 7.52 (m, 2H), 7.47 – 7.83 (m, 7H), 6.83 – 6.75 (m, 4H), 6.21 (s, 1H), 3.77 (s, 3H), 3.23 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 170.0, 154.9, 151.1, 137.0, 134.1, 132.2, 129.4, 129.2, 129.1, 129.0, 127.5, 117.0, 114.7, 80.9, 55.6, 33.0; IR (neat): 2922, 1711 (s), 1506, 1362,


1222, 1040, 745, 613; MS (ESI, m/z) 512 ($M + Na^+$); HRESIMS Calcd for $[C_{22}H_{20}BrNNaO_5S]^+$ ($M + Na^+$) 512.0138, found 512.0138.



General procedure for the synthesis of **4**:

2,6-dimethylpyridine *N*-oxide (73.8 mg, 0.6 mmol), ArSH (0.6 mmol), 4Å MS (60.0 mg) and Zn(OTf)₂ (10.9 mg, 0.03 mmol) were added in this order to the ynamide **1** (0.30 mmol) in DCE (3.0 mL) at room temperature. The reaction mixture was stirred at 80 °C and the progress of the reaction was monitored by TLC. The reaction typically took 3 h. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: hexanes/ethyl acetate) to afford the desired product **4**.

N-methyl-2-phenyl-2-(phenylthio)-*N*-tosylacetamide (**4a**)




4a

Compound **4a** was prepared in 77% yield according to the general procedure (Table 3, entry 1). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, 2H, $J = 8.4$ Hz), 7.31 – 7.17 (m, 12H), 5.86 (s, 1H), 3.16 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.1, 144.9, 135.5, 135.2, 133.4, 133.1, 129.7, 128.9, 128.8, 128.6, 128.2, 128.1, 127.5, 57.1, 33.4, 21.5; IR (neat): 3060, 2923, 1694 (s), 1359, 1168, 1070, 693, 548;

MS (ESI, m/z) 434 (M + Na⁺); HRESIMS Calcd for [C₂₂H₂₁NNaO₃S₂]⁺ (M + Na⁺) 434.0855, found 434.0857.


***N*-methyl-*N*-(methylsulfonyl)-2-phenyl-2-(phenylthio)acetamide (4b)**



4b

Compound **4b** was prepared in 66% yield according to the general procedure (Table 3, entry 2). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.23 (m, 10H), 5.67 (s, 1H), 3.22 (s, 3H), 2.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 135.0, 133.7, 133.0, 129.1, 128.9, 128.8, 128.5, 128.4, 57.2, 40.8, 33.1; IR (neat): 3059, 2927, 1692 (s), 1354, 1165, 1075, 964, 748, 517; MS (ESI, m/z) 358 (M + Na⁺); HRESIMS Calcd for [C₁₆H₁₇NNaO₃S₂]⁺ (M + Na⁺) 358.0542, found 358.0546.


***N*-((4-bromophenyl)sulfonyl)-*N*-methyl-2-phenyl-2-(phenylthio)acetamide (4c)**



4c

Compound **4c** was prepared in 62% yield according to the general procedure (Table 3, entry 3). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.51 (m, 2H), 7.47 – 7.45 (m, 2H), 7.29 – 7.22 (m, 10H), 5.68 (s, 1H), 3.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 137.2, 135.0, 133.3, 133.2, 132.3, 129.2, 129.1, 129.0, 128.8, 128.7, 128.4, 128.3, 57.3, 33.5; IR (neat): 2922, 2851, 1693 (s), 1357, 1165, 748, 664, 593; MS (ESI, m/z) 498 (M + Na⁺); HRESIMS Calcd for [C₂₁H₁₈BrNNaO₃S₂]⁺ (M + Na⁺) 497.9804, found 497.9805.


***N*-butyl-2-phenyl-2-(phenylthio)-*N*-tosylacetamide (4d)**



4d

Compound **4d** was prepared in 76% yield according to the general procedure (Table 3, entry 4). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.51 (d, 2H, $J = 8.4$ Hz), 7.29 – 7.15 (m, 12H), 5.73 (s, 1H), 3.70 – 3.55 (m, 2H), 2.39 (s, 3H), 1.53 – 1.43 (m, 2H), 1.25 – 1.19 (m, 2H), 0.84 (t, 3H, $J = 7.2$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 144.7, 136.0, 135.5, 133.6, 133.1, 129.6, 128.8, 128.7, 128.6, 128.2, 128.1, 127.6, 57.1, 47.0, 31.3, 21.5, 19.9, 13.5; IR (neat): 2956, 2873, 1693 (s), 1357, 1169, 1085, 1024, 910, 694, 590; MS (ESI, m/z) 476 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{25}\text{H}_{27}\text{NNaO}_3\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 476.1325, found 476.1327.


***N*-benzyl-2-phenyl-2-(phenylthio)-*N*-tosylacetamide (4e)**



4e

Compound **4e** was prepared in 64% yield according to the general procedure (Table 3, entry 5). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, 2H, $J = 8.0$ Hz), 7.29 – 7.11 (m, 13H), 7.08 – 7.04 (m, 4H), 5.41 (s, 1H), 5.06 (d, 1H, $J = 16.4$ Hz), 4.78 (d, 1H, $J = 16.8$ Hz), 2.42 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.8, 144.9, 136.1, 135.7, 134.8, 133.3, 133.0, 129.5, 128.9, 128.8, 128.7, 128.5, 128.3, 128.2, 128.1, 127.7, 127.1, 57.0, 49.5, 21.6; IR (neat): 3062, 2924, 1699 (s), 1358, 1169, 748, 587; MS (ESI, m/z) 510 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{28}\text{H}_{25}\text{NNaO}_3\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 510.1168, found 510.1167.


2-(4-bromophenyl)-*N*-methyl-2-(phenylthio)-*N*-tosylacetamide (**4f**)



4f

Compound **4f** was prepared in 70% yield according to the general procedure (Table 3, entry 6). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.41 (d, 2H, $J = 8.4$ Hz), 7.30 (d, 2H, $J = 8.4$ Hz), 7.21 – 7.09 (m, 9H), 5.76 (s, 1H), 3.10 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.9, 145.1, 135.2, 134.9, 133.4, 132.9, 131.6, 130.5, 129.8, 129.0, 128.4, 127.3, 122.4, 56.3, 33.5, 21.6; IR (neat): 3058, 2954, 2923, 1693 (s), 1596, 1486, 1359, 1168, 1011, 811, 590; MS (ESI, m/z) 512 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{22}\text{H}_{20}\text{BrNNaO}_3\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 511.9960, found 511.9961.


2-(4-methoxyphenyl)-*N*-methyl-2-(phenylthio)-*N*-tosylacetamide (**4g**)



4g

Compound **4g** was prepared in 83% yield according to the general procedure (Table 3, entry 7). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, 2H, $J = 8.4$ Hz), 7.23 – 7.21 (m, 9H), 6.81 – 6.78 (m, 2H), 5.81 (s, 1H), 3.79 (s, 3H), 3.16 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 170.3, 159.5, 144.8, 135.2, 133.6, 133.1, 130.0, 129.7, 128.8, 128.0, 127.5, 127.3, 114.0, 56.4, 55.2, 33.4, 21.6; IR (neat): 2955, 2927, 1694 (s), 1510, 1359, 1169, 811, 591; MS (ESI, m/z) 464 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{NNaO}_4\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 464.0961, found 464.0961.


2-((4-chlorophenyl)thio)-*N*-methyl-2-phenyl-*N*-tosylacetamide (**4h**)



4h

Compound **4h** was prepared in 71% yield according to the general procedure (Table 3, entry 8). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, 2H, *J* = 8.4 Hz), 7.27 – 7.26 (m, 5H), 7.20 – 7.16 (m, 6H), 5.82 (s, 1H), 3.16 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 145.0, 135.1, 134.9, 134.5, 131.7, 129.7, 129.0, 128.8, 128.7, 128.3, 127.5, 57.2, 33.4, 21.5; IR (neat): 3063, 2924, 1694 (s), 1476, 1360, 1168, 1013, 813, 665, 548; MS (ESI, *m/z*) 468 (M + Na⁺); HRESIMS Calcd for [C₂₂H₂₀ClNNaO₃S₂]⁺ (M + Na⁺) 468.0465, found 468.0468.


2-((4-bromophenyl)thio)-*N*-methyl-2-phenyl-*N*-tosylacetamide (4i)



4i


Compound **4i** was prepared in 73% yield according to the general procedure (Table 3, entry 9). Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, 2H, *J* = 8.4 Hz), 7.33 – 7.31 (m, 2H), 7.28 – 7.26 (m, 5H), 7.19 (d, 2H, *J* = 8.0 Hz), 7.10 (d, 2H, *J* = 8.8 Hz), 5.83 (s, 1H), 3.16 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 145.0, 135.1, 135.0, 132.4, 132.0, 129.7, 128.8, 128.7, 128.4, 127.5, 122.7, 57.1, 33.5, 21.6; IR (neat): 3062, 2924, 1694 (s), 1473, 1359, 1168, 1009, 813, 665, 548; MS (ESI, *m/z*) 512 (M + Na⁺); HRESIMS Calcd for [C₂₂H₂₀BrNNaO₃S₂]⁺ (M + Na⁺) 511.9960, found 511.9961.

2-((2-bromophenyl)thio)-*N*-methyl-2-phenyl-*N*-tosylacetamide (4j)




Compound **4j** was prepared in 62% yield according to the general procedure (Table 3, entry 10). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.57 – 7.55 (m, 1H), 7.50 – 7.47 (m, 2H), 7.32 – 7.26 (m, 5H), 7.17 – 7.15 (m, 3H), 7.14 – 7.07 (m, 2H), 6.00 (s, 1H), 3.20 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.6, 145.0, 135.1, 134.9, 134.8, 133.3, 133.1, 129.7, 129.0, 128.8, 128.7, 128.4, 127.8, 127.6, 127.0, 55.7, 33.5, 21.6; IR (neat): 2924, 1693 (s), 1359, 1169, 1073, 1019, 665, 548; MS (ESI, m/z) 512 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{22}\text{H}_{20}\text{BrNNaO}_3\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 511.9960, found 511.9961.

***N*-methyl-2-phenyl-2-(*p*-tolylthio)-*N*-tosylacetamide (4k)**



Compound **4k** was prepared in 72% yield according to the general procedure (Table 3, entry 11). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.48 (d, 2H, $J = 8.4$ Hz), 7.27 – 7.25 (m, 5H), 7.19 (d, 2H, $J = 8.0$ Hz), 7.14 (d, 2H, $J = 8.0$ Hz), 7.01 (d, 2H, $J = 8.0$ Hz), 5.76 (s, 1H), 3.16 (s, 3H), 2.40 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.2, 144.8, 138.4, 135.6, 135.2, 133.8, 129.6, 129.5, 128.8, 128.6, 128.1, 127.6, 57.4, 33.4, 21.5, 21.1; IR (neat): 2923, 1694 (s), 1493, 1359, 1168, 1071, 813, 665, 548; MS (ESI, m/z) 448 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{NNaO}_3\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 448.1012, found 448.1014.


2-((4-methoxyphenyl)thio)-*N*-methyl-2-phenyl-*N*-tosylacetamide (4l)



4I

Compound **4I** was prepared in 75% yield according to the general procedure (Table 3, entry 12). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, 2H, $J = 8.4$ Hz), 7.26 – 7.16 (m, 9H), 6.73 (d, 2H, $J = 8.4$ Hz), 5.67 (s, 1H), 3.78 (s, 3H), 3.15 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 160.2, 144.8, 136.6, 135.6, 135.3, 129.7, 128.8, 128.5, 128.1, 127.6, 123.5, 114.4, 58.0, 55.2, 33.4, 21.6; IR (neat): 2955, 1694 (s), 1592, 1494, 1359, 1171, 813, 665, 548; MS (ESI, m/z) 464 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{23}\text{H}_{23}\text{NNaO}_4\text{S}_2]^+$ ($\text{M} + \text{Na}^+$) 464.0961, found 464.0961.


***N*-((4-bromophenyl)sulfonyl)-*N*-methyl-2-(methyl(phenyl)amino)-2-phenylacetamide (**5**)**



5


Compound **5** was prepared in 58% yield according to the general procedure except using 2-bromopyridine *N*-oxide as oxidant (eq 1). Pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.48 (m, 4H), 7.37 – 7.32 (m, 3H), 7.26 – 7.21 (m, 2H), 7.13 – 7.11 (m, 2H), 6.82 – 6.75 (m, 3H), 6.27 (s, 1H), 3.27 (s, 3H), 2.74 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.3, 149.3, 137.4, 134.6, 132.2, 129.4, 129.3, 129.1, 129.0, 128.9, 128.5, 118.2, 113.2, 65.7, 34.5, 33.1; IR (neat): 2923, 1705 (s), 1598, 1504, 1360, 1172, 1069, 747, 611; MS (ESI, m/z) 495 ($\text{M} + \text{Na}^+$); HRESIMS Calcd for $[\text{C}_{22}\text{H}_{21}\text{BrN}_2\text{NaO}_3\text{S}]^+$ ($\text{M} + \text{Na}^+$) 495.0348, found 495.0353.

2-phenoxy-2-phenylethanol (6a**)**



Compound **6a** was prepared in 76% yield according to the known procedure.⁴ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.24 (m, 5H), 7.21 – 7.17 (m, 2H), 6.91 – 6.86 (m, 3H), 5.28 – 5.25 (m, 1H), 3.95 – 3.81 (m, 2H), 2.34 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 157.8, 137.8, 129.4, 128.7, 128.1, 126.3, 121.2, 115.9, 81.1, 67.5; IR (neat): 3400 (br), 2921, 1494, 1453, 1240, 1042, 750, 693; MS (ESI, m/z) 237 (M + Na⁺); HRESIMS Calcd for [C₁₄H₁₄NaO₂]⁺ (M + Na⁺) 237.0886, found 237.0883.

methyl 2-phenoxy-2-phenylacetate (**6b**)



Compound **6b** was prepared in 80% yield according to the known procedure.⁴ Pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.58 – 7.56 (m, 2H), 7.39 – 7.33 (m, 3H), 7.26 – 7.22 (m, 2H), 6.97 – 6.93 (m, 3H), 5.64 (s, 1H), 3.69 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 157.2, 135.4, 129.5, 128.9, 128.8, 127.0, 121.8, 115.4, 78.6, 52.6; IR (neat): 3033, 2953, 1759 (s), 1597, 1495, 1235, 1061, 754, 691; MS (ESI, m/z) 265 (M + Na⁺); HRESIMS Calcd for [C₁₅H₁₄NaO₃]⁺ (M + Na⁺) 265.0835, found 265.0836.

Reference:


- Li, L.; Shu, C.; Zhou, B.; Yu, Y.-F.; Xiao, X.-Y.; Ye, L.-W. *Chem. Sci.* **2014**, *5*, 4057.
- Zhou, A.-H.; He, Q.; Shu, C.; Yu, Y.-F.; Liu, S.; Zhao, T.; Zhang, W.; Lu, X.; Ye,

L.-W. *Chem. Sci.* **2015**, *6*, 1265.



3. Yao, B.-B.; Liang, Z.-J.; Niu, T.-M.; Zhang, Y.-H. *J. Org. Chem.* **2009**, *74*, 4630.

4. Li, L.; Zhou, B.; Ye, L.-W. *Chin. J. Org. Chem.* **2015**, *35*, 655.

7.831
7.825
7.820
7.809
7.804
7.798
7.739
7.734
7.729
7.717
7.712
7.706
7.371
7.363
7.354
7.347
7.311
7.303
7.294
7.286





3.170



134.8
132.4
131.3
129.0
128.9
128.2
127.9
122.1



83.2
77.3
77.0
76.7
69.2


39.2



7.647
7.623
7.592
7.570
7.396
7.388
7.379
7.372
7.364
7.345
7.322
7.316
7.304
7.296
7.288

// }
// }







7.826
7.804
7.707
7.685
7.358
7.349
7.340
7.334
7.291
7.282
7.275

5.837
5.821
5.795
5.779
5.753
5.737
5.326
5.281
5.268
5.243

4.079
4.063



140.1
136.1
135.0
132.5
129.1
129.0
128.6
128.4
126.0



106.9


85.2


77.3
77.0
76.7


68.9


39.3













7.810
7.789
7.738
7.716
7.297
7.274
7.250


3.167



135.0
134.0
132.6
132.5
129.1
128.6
120.8

84.1
77.3
77.0
76.7
68.4


39.3





200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0

f1 (ppm)

7.808
7.787
7.737
7.715
7.435
7.414
7.222
7.200




3.166



135.1
132.8
132.6
131.5
129.1
122.2
121.3

84.3
77.3
77.0
76.7
68.5

39.3




200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0

f1 (ppm)

7.817
7.796
7.725
7.703



7.264
7.244
7.112
7.092



3.165



2.337



138.3
136.1
132.5
131.6
129.2
129.1
129.0



119.1

82.5
77.3
77.0
76.7

69.3

39.4

21.4





200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0

f1 (ppm)

7.799
7.778
7.720
7.699
7.342
7.310
7.274
7.256
6.858
6.817
6.221
6.180

3.123



140.1
136.1
135.0
132.5
129.1
129.0
128.6
128.4
126.0



106.9



85.2

77.3
77.0
76.7

68.9

39.3





— 144.9

133.1
└─┘

132.6
└─┘

131.4
└─┘

129.8
└─┘

127.7
└─┘

121.8
└─┘

121.6
└─┘

— 85.0

77.3
└─┘



77.0
└─┘





76.7
└─┘


— 68.1

— 39.1


— 21.6









7.953
7.935
7.894
7.874
7.660
7.642
7.623
7.548
7.529
7.510
7.400
7.380




3.239




2.455





7.702
7.681
7.307
7.286
7.278
7.259
7.241
7.150
7.114





4.031




3.269




2.426






7.491
7.479
7.467
7.458
7.390
7.384
7.376
7.372
7.256
7.253
7.235
7.213
7.191
7.171
6.998
6.980
6.901
6.881
6.187




3.192




2.401



2a





—169.9

—157.2

—145.0

135.0

134.4

129.7

129.6

128.9

127.9


122.8


—115.6



—79.5


—33.0



—21.6
















7.870
7.849
7.665
7.644
7.492
7.474
7.455
7.383
7.364
7.344
7.321
7.303
7.263
7.250
7.244
7.225
7.176
7.156
7.136
7.000
6.981
6.949
6.930
6.912
6.674
6.654

5.332













7.560
7.538
7.503
7.481
7.465
7.452
7.444
7.431
7.254
7.237
7.217
7.098
7.076
7.055
7.022
7.004
6.986
6.859
6.839
6.351

3.227







7.562
7.540
7.529
7.507
7.383
7.364
7.348
7.329
7.253
7.243
7.223
7.195
7.171
7.160
7.082
7.062
7.033
7.015
6.997
6.868
6.848
6.325



3.243






— 169.4
— 164.2
— 161.7
— 156.7


136.9
136.5
136.4
132.3
130.6
129.8
129.3
123.0
122.9
122.5
116.3
116.1
115.5
114.6
114.4


79.1
77.3
77.0
76.7


— 33.1























7.596
7.573
7.561
7.539
7.406
7.371
7.329
7.314
7.277
7.256
7.238
7.109
7.071
7.063
7.057
7.018
6.987
6.969
6.950
6.931
6.911


5.791
5.783

3.303










136.7
133.4
132.3
129.5
129.4
129.2
129.1
127.7
127.2

116.9
116.6

79.9
77.3
77.0
76.7



33.0




169.4

155.5




f1 (ppm)






7.556
7.534
7.466
7.445
7.417
7.407
7.255
7.141
7.122
7.094
7.047
6.814
6.795
— 6.351

— 3.208








7.540
7.518
7.466
7.444
7.413
7.390
7.376
6.829
6.806
6.773
6.750

—6.206

—3.766

—3.225








7.482
7.461
7.307
7.285
7.279
7.261
7.259
7.241
7.239
7.228
7.220
7.216
7.197
7.176

5.856

3.162

2.403






7.341
7.311
7.285
7.271
7.260
7.254
7.232


5.670

3.220

2.882



4b



5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0



7.04
3.21

1.01

3.00

3.00



f1 (ppm)





7.541
7.539
7.531
7.522
7.517
7.512
7.469
7.464
7.452
7.447
7.294
7.275
7.258
7.231
7.216

5.676

3.195







7.520
7.499
7.292
7.271
7.265
7.257
7.246
7.236
7.228
7.219
7.212
7.198
7.187
7.166


5.733

3.701
3.565
3.527
3.589
3.553

2.391

1.529
1.508
1.486
1.468
1.428
1.247
1.228
1.210
1.191
0.860
0.842
0.823







7.581
7.561
7.289
7.281
7.273
7.253
7.221
7.206
7.202
7.185
7.161
7.144
7.125
7.107
7.078
7.061
7.041



5.411

5.081
5.040

4.804
4.762

2.417








7.423
7.402
7.313
7.292
7.206
7.194
7.183
7.178
7.172
7.149
7.140
7.121
7.111
7.090

5.760

3.097

2.331







7.513
7.492
7.234
7.233
7.224
7.209
6.800
6.788
6.783



5.805


3.790



3.159


2.405











—169.9

—145.0

135.1

135.0

132.4

132.0

129.7

128.8

128.7

128.4

127.5

122.7

77.3



77.0


76.7

—57.1

—33.5

—21.6





—169.6



—145.0
—135.1
—134.9
—134.8
—133.3
—133.1
—129.7
—129.0
—128.8
—128.7
—128.4
—127.8
—127.6
—127.0

—77.3
—77.0
—76.7

—55.7

—33.5

—21.6






7.489
7.468
7.265
7.251
7.195
7.175
7.145
7.125
7.021
7.001


5.757

3.155

2.396
2.305








7.484
7.463
7.264
7.259
7.249
7.237
7.210
7.188
7.165
6.743
6.721


5.666


3.777

3.151

2.407








7.373
7.355
7.337
7.318
7.293
7.277
7.244
7.207
7.188
7.169
6.912
6.893
6.879
6.860


5.278
5.270
5.258
5.250



3.942
3.913
3.892
3.818

2.337



6a





7.577
7.560
7.385
7.369
7.350
7.344
7.326
7.263
7.242
7.223
6.968
6.950
6.929

5.637

3.685

